SPC 8490
Alternative Names: SPC8490Latest Information Update: 04 Dec 2019
At a glance
- Originator Celgene Corporation
- Class Antineoplastics
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 19 Jun 2001 Phase-I clinical trials for Breast cancer in United Kingdom (Unknown route)
- 19 Jun 2001 Phase I study in volunteers initiated in the UK